{"entity":{"id":"nct05862324","kind":"trial","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","aka":[],"tldr":"A phase 1/2 trial of TAC01-CLDN18.2 in advanced solid tumours, run by Triumvira Immunologics, Inc., active and no longer recruiting.","summary":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) is a phase 1/2 interventional study registered as NCT05862324 by Triumvira Immunologics, Inc., with 113 participants enrolled, started 2023-08-23 and due to reach its primary completion in 2027-08-01. Interventions recorded: TAC01-CLDN18.2.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05862324","url":"https://clinicaltrials.gov/study/NCT05862324"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tac01-cldn18-2"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05862324","phase":"1/2","setting":"A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors","sponsor":"Triumvira Immunologics, Inc.","enrolled":113,"outcomes":[]},"route":"/trials/nct05862324/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/"}]}}